We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+12.4%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$237M
AUM Growth
+$61.7M
Cap. Flow
+$42.4M
Cap. Flow %
17.92%
Top 10 Hldgs %
29.74%
Holding
101
New
35
Increased
9
Reduced
16
Closed
26

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$7.31M
2
BRKR icon
Bruker
BRKR
+$5.5M
3
LIVN icon
LivaNova
LIVN
+$4.1M
4
SPNC
Spectranetics Corp
SPNC
+$3.7M
5
COO icon
Cooper Companies
COO
+$3.58M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$5.02M
2
BHC icon
Bausch Health
BHC
+$4.13M
3
CYBX
CYBERONICS INC
CYBX
+$3.65M
4
ABT icon
Abbott
ABT
+$3.22M
5
VAR
Varian Medical Systems, Inc.
VAR
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 56.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
CALL
Edwards Lifesciences
EW
$53.8B
$3.95M 1.67%
+150,000
New +$3.9M
AGN
27
DELISTED
Allergan plc
AGN
$3.94M 1.66%
12,600
+5,600
+80% +$1.67M
BAX icon
28
CALL
Baxter International
BAX
$14.3B
$3.81M 1.61%
+100,000
New +$3.66M
TMO icon
29
PUT
Thermo Fisher Scientific
TMO
$222B
$3.55M 1.5%
+25,000
New +$3.33M
XLI icon
30
PUT
State Street Industrial Select Sector SPDR ETF
XLI
$34.7B
$3.45M 1.45%
+65,000
New +$3.49M
COO icon
31
Cooper Companies
COO
$15B
$3.35M 1.42%
+100,000
New +$3.58M
COO icon
32
PUT
Cooper Companies
COO
$15B
$3.35M 1.42%
+100,000
New +$3.58M
CAH icon
33
PUT
Cardinal Health
CAH
$55.7B
$3.12M 1.32%
+35,000
New +$2.97M
HCA icon
34
PUT
HCA Healthcare
HCA
$89.2B
$3.04M 1.28%
+45,000
New +$3.14M
CYNA
35
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$3.01M 1.27%
194,461
– –
LLY icon
36
Eli Lilly
LLY
$1.09T
$2.91M 1.23%
34,500
-9,750
-22% -$809K
ARAY icon
37
Accuray
ARAY
$35.1M
$2.9M 1.23%
430,000
-283,700
-40% -$1.82M
A icon
38
Agilent Technologies
A
$42.3B
$2.72M 1.15%
+65,000
New +$2.51M
RMD icon
39
PUT
ResMed
RMD
$32.2B
$2.69M 1.13%
+50,000
New +$2.82M
ELGX
40
DELISTED
Endologix Inc
ELGX
$2.67M 1.13%
27,000
+6,490
+32% +$696K
AFFX
41
DELISTED
Affymetrix Inc
AFFX
$2.62M 1.1%
259,309
-20,691
-7% -$191K
ZBH icon
42
Zimmer Biomet
ZBH
$18.7B
$2.56M 1.08%
+25,750
New +$2.52M
KITE
43
DELISTED
Kite Pharma, Inc.
KITE
$2.55M 1.08%
41,450
-7,300
-15% -$514K
ALXN
44
DELISTED
Alexion Pharmaceuticals
ALXN
$2.43M 1.03%
12,750
+250
+2% +$43.7K
QGENF
45
DELISTED
QIAGEN NV
QGENF
$2.17M 0.92%
78,668
-6,332
-7% -$175K
SGYP
46
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.11M 0.89%
372,800
-27,200
-7% -$166K
SYK icon
47
Stryker
SYK
$134B
$2.09M 0.88%
22,500
-52,500
-70% -$5.02M
EVHC
48
DELISTED
Envision Healthcare Holdings Inc
EVHC
$2.08M 0.88%
+26,720
New +$2.31M
ASXC
49
DELISTED
Asensus Surgical, Inc.
ASXC
$2.01M 0.85%
62,339
– –
EWA icon
50
CALL
iShares MSCI Australia ETF
EWA
$1.46B
$1.9M 0.8%
+100,000
New +$1.89M
1
2
3 4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2015 Portfolio in Review

As of Q4 2015, Pura Vida Investments held 101 positions worth $237M, up 35% from $175M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Pura Vida Investments deployed $42.4M of net new capital in Q4 2015, opening 35 new positions and adding to 9 existing holdings. Its largest new stake was Baxter International: 200,000 shares worth $7.63M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 66% a quarter earlier.

On the sell side, the largest reduction was Stryker, an estimated $5.02M trimmed.

  • Pura Vida Investments's largest Q4 2015 buy was Baxter International: 200,000 shares worth $7.63M.
  • Pura Vida Investments added most to Accendra Health in Q4 2015, an estimated $2.75M increase.
  • Pura Vida Investments's biggest Q4 2015 reduction was Stryker, cutting an estimated $5.02M.
  • Pura Vida Investments fully exited Bausch Health in Q4 2015, selling an estimated $4.13M.
  • Pura Vida Investments's ten largest holdings make up 30% of its $237M portfolio in Q4 2015.
  • Pura Vida Investments opened 35 new positions and closed 26 in Q4 2015.
  • Pura Vida Investments's portfolio value rose 35% quarter-over-quarter to $237M.

Based on Pura Vida Investments's 13F filing for Q4 2015, filed 16 Feb 2016.